Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- Pharma is bracing for the impact of generics as a number of patents expire. Novartis stands to lose most on Sandostatin LAR, which has pulled in €1.5Bn in annual sales
- The US Department of Justice has fined Shire $350M as threatened for “flagrant and systemic kickback activity”
- Ethypharm (FR) has acquired Martindale Pharma (UK), which specialises in essential medicines for opioid addiction, emergency care and sterile injectables
- Evotec is partnering with Asahi Kasei pharma to apply its integrated drug discovery platform to an ion channel target
- Allergan and Hungarian pharma Gedeon Richter have encouraging results from a late-stage study of patients with symptomatic uterine fibroids
- BMS is pulling out of the lung cancer combo race, effectively handing the space to Merck.
- Lysogene’s LYS-GM101 for GM1 Gangliosidosis, a severe neurodegenerative disease, received Rare Pediatric Disease Designation to make it eligible for priority review by the FDA
- The FDA has hammered out guidelines on interchangeability, one of the biggest hurdles for biosimilars to make it to market
- Italian gene therapy company, Genenta, has recruited GSK vet Carlo Russo as CMO. Russo played a key role in the market approval of the first ex-vivo gene therapy, Strimvelis.
Trump or Raw Chicken?
Images from jdross75, Susan Schmitz, meunière, MoonAngelEyes / shutterstock.com